Role of Endothelin-1 in Hypertension
- 1 October 1999
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 34 (4) , 876-881
- https://doi.org/10.1161/01.hyp.34.4.876
Abstract
Endothelin-1 (ET-1) is overexpressed in the vascular wall in certain models of experimental hypertension: deoxycorticosterone acetate salt-treated rats, deoxycorticosterone acetate salt-treated spontaneously hypertensive rats (SHR), stroke-prone SHR, Dahl salt-sensitive rats, angiotensin II-infused rats, and 1-kidney 1 clip Goldblatt rats; it is not overexpressed in SHR, 2-kidney 1-clip hypertensive rats, or L-NAME-treated rats. In hypertensive rats without generalized vascular overexpression, however, expression of ET-1 was often enhanced in intramyocardial coronary arteries, suggesting a role of endothelin in myocardial ischemia in hypertension. In rats overexpressing ET-1, ET(A/B) and ET(A)-selective receptor antagonists lowered blood pressure and reduced vascular growth, particularly in small arteries, beyond what could be attributed to blood pressure lowering, suggesting a direct effect of ET-1 on growth. Hypertensive rats treated with endothelin antagonists are protected from stroke and renal injury. The ET(A/B) antagonist bosentan induced blood-pressure reductions in mildly hypertensive patients similar to those achieved with an angiotensin-converting enzyme inhibitor. Moderately to severely hypertensive patients presented with enhanced expression of prepro-ET-1 mRNA in the endothelium of subcutaneous resistance arteries, suggesting that these stages of hypertension may respond particularly well to endothelin antagonism. Hypertensive patients with coronary artery disease have increased arterial expression of ET-1, and increased plasma levels of immunoreactive endothelin have been described in black patients. ET-1 plays an important role in atherosclerosis, for which hypertension is an important risk factor. Thus, ET-1 may be involved in experimental and human hypertension. Endothelin antagonists may prove effective as disease-modifying agents if they are shown clinically, as they are experimentally, to offer target organ protection and reduce long-term complications of hypertension. This remains to be demonstrated in humans.Keywords
This publication has 56 references indexed in Scilit:
- Enhanced Expression of the Endothelin-1 Gene in Blood Vessels of DOCA-Salt Hypertensive Rats: Correlation with Vascular StructureJournal of Vascular Research, 1996
- Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive ratsJournal Of Hypertension, 1995
- Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive ratsLife Sciences, 1995
- Effect of Chronic Treatment of Adult Spontaneously Hypertensive Rats With an Endothelin Receptor AntagonistHypertension, 1995
- Deoxycorticosterone Acetate Plus Salt Induces Overexpression of Vascular Endothelin-1 and Severe Vascular Hypertrophy in Spontaneously Hypertensive RatsHypertension, 1995
- Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy.Hypertension, 1994
- Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats.Hypertension, 1993
- Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats.Hypertension, 1993
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- Vascular binding sites and biological activity of vasopressin in DOCA-salt hypertensive ratsJournal Of Hypertension, 1988